Association between primary antiphospholipid syndrome (PAPS) and antiphospholipid syndrome secondary to systemic lupus erythematosus (SAPS) and atherosclerosis: Preliminary observation;Zespół antyfosfolipidowy pierwotny (PAPS) i wtórny do tocznia rumieniowatego układowego (SAPS) a miażdżyca tȩtnic; wstȩpna obserwacja

Reumatologia

Volumn 43, Issue 2, 2005, Pages 48-56

  Meissner, Martyna ^a   Butkiewicz, Lidia ^a   Chwalińska Sadowska, Hanna ^a   Za̧bek, Jakub ^a   Małek, Grzegorz ^b   Tomkowski, Witold ^b  

^a INSTITUTE OF RHEUMATOLOGY   (Poland)

^b INSTYTUT GRU LICY I CHORÓB P UC   (Poland)

Author keywords

Anti B2GP1 antibodies; Anticardiolipin antibodies (aCL abs); Antiphospholpid antibodies (aPL abs); Antiphospholpid syndrome (APS); Anty oxidized low density lipoproteins antibodies (anti oxy LDL abs); Atherosclerosis

Indexed keywords

ANTINUCLEAR ANTIBODY; BETA2 GLYCOPROTEIN 1; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; DNA ANTIBODY; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M ANTIBODY; INTERCELLULAR ADHESION MOLECULE 1; LUPUS ANTICOAGULANT; OXIDIZED LOW DENSITY LIPOPROTEIN; PROTEIN ANTIBODY; VASCULAR CELL ADHESION MOLECULE 1;

ANTIBODY DETECTION; ANTIGEN EXPRESSION; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CAROTID ARTERY; CELL ACTIVITY; CLINICAL ARTICLE; COLOR ULTRASOUND FLOWMETRY; CONTROLLED STUDY; CORRELATION ANALYSIS; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION; FEMALE; HUMAN; HUMORAL IMMUNITY; LONG TERM CARE; MALE; RISK FACTOR; SERODIAGNOSIS; STATISTICAL ANALYSIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 20044364031     PISSN: 00346233     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Amengual O, Atsumi T, Khamashta MA, et al. Autoantibodies againts oxidized low-density lipoprotein in antiphospholipid syndrome. Br J Rheumatol 1997; 36: 964-8.
2. Asherson RA, Khamashta MA, Ordi-Ros J, et al. The primary antiphospholipid syndrome: major clinical and serological features. Medicine (Baltimore) 1989; 68: 366-74.
3. Asherson RA. Catastrophic antiphospholipid syndrome. Clues to the patogenesis from a series of 80 patients. Medicine (Baltimore) 2001; 80: 1-23.
4. Blank M, Cohen J, Toder V, et al. Induction of anti-phospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies. Proc Natl Acad Sci USA 1991; 88: 3069-73.
5. Blank M, Shoenfeld Y, Cabilly S, et al. Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides. Proc Natl Acad Sci USA 1999; 96: 5164-8.
6. Blank M, Krause I, Fridkin M, et al. Bacterial induction of autoantibodies to beta2-glycoprotein-1 accounts for the infectious etiology of antiphospholipid syndrome. J Clin Invest 2002; 109: 797-804.
7. Doria A, Shoenfeld Y, Wu R, et al. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2003; 62: 1071-7.
8. George J, Shoenfeld Y, Gilburd B, et al. Requiste role for interleukin-4 in the acceleration of fatty streaks induced by heat shock protein 65 or Mycobacterium tuberculosis. Circ Res 2000; 86: 1203-10.
9. George J, Afec A, Gilburd B, et al. Atherosclerosis in LDL-receptor knockout mice is accelerated by immunization with anticardiolipin antibodies. Lupus 1997; 6: 723-9.
10. Gharavi AE, Chaimovich H, Cucurull E, et al. Induction of antiphospholipid antibodies by immunization with synthetic viral and bacterial peptides. Lupus 1999; 8: 449-55.
11. Gharavi AE, Pierangeli SS, Espinola RG, et al. Antiphospholipid antibodies induced in mice by immunization with a cytomegalovirus-derived peptide cause thrombosis and activation of endothelial cells in vivo. Arthritis Rheum 2002; 46: 545-52.
12. Holers VM, Girardi G, Mo L, et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med 2002; 195: 211-20.
13. Hughes GRV. Thrombosis, abortion, cerebral disease and lupus anticoagulant. Br Med J 1983; 187: 1088-9.
14. Levine SR, Salowich-Palm L, Sawaya KL, et al. IgG anticardiolipin antibody titer >40GPL and the risk of subsequent thrombo-occlusive events and death. A prospective cohort study. Stroke 1997; 28: 1660-5.
15. Puurunen M, Manttari M, Manninen V, et al. Antibody against oxidized LDL predicting myocardial infarction. Arch Intern Med 1994; 154: 2605-9.
16. Rand JH. Effects of antiphospholipid antibodies upon the morphology and anticoagulation function of annexin-V (abstract). Lupus 2002; 11 (9) (suppl.): 571.
17. Randt JH. Molecular of pathogenesis of the antiphospholipid syndrome. Circ Res 2002; 90: 29-37.
18. Shoenfeld Y, Harats D, Wick G, et al. Atherosclerosis and autoimmunity. Elservier, Amsterdam, 2001: 1-370.
19. Shoenfeld Y, Sherer Y, George J, et al. Autoantibodies associated with athrosclerosis. Ann Med 2000; 32 (suppl 1): 37-40.
20. Sletnes KE, Smith P, Abdenoor M, et al. APL after myocardial infarction and their relation to mortality, reinfarction, and non-haemorrhagic stroke. Lancet 1992; 339: 451-3.
21. Tsakiris DA, Marbet GA, Bukat F, et al. Anticardiolipin antibodies and coronary heart disease. Eur Heart J, 1992; 13: 1645-8.
22. Vaarala O, Monttari M, Manninen V, et al. Anticardiolipin antibodies and risk of myocardial infarction in a prospective cohort a middle-aged men. Circulation 1995; 91: 23-7.
23. Vaarala O, Alfthan G, Jauhiainen M, et al. Crossreaction between antibodies to oxidized low density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 1993; 2: 923-5.
24. Vaarala O. Atherosclerosis in SLE and Hughes syndrome. Lupus 1997; 6: 489-90.
25. Vaarala O, Puurunen M, Lukka M, et al. Affinity-purified cardiolipin-binding antibodies show heterogeneity in their inding to oxidized low-density lipoprotein. Clin Exp Immunol 1996; 104: 269-74.
26. Zuckerman E, Toubi E, Shiran A, et al. Anticardiolipin antibodies and acute myocardial infarction in non-systemic lupus erythematosus: a controlled prospective study. Am J Med 1996; 101: 381-6.